Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report

Classic Kaposi's sarcoma (KS) is a disease with low mortality but high morbidity. The optimum treatment of KS depends upon several factors, including location of lesions, disease progression, severity of symptoms and patient preference. We report the long-term response to the use of intralesion...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirza, Yasir Azim, Altamura, Davide, Hirbod, Torkan, Verdolini, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2015
Materias:
Published online: February, 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357673/
https://www.ncbi.nlm.nih.gov/pubmed/25848347
http://dx.doi.org/10.1159/000369490
_version_ 1782361176950177792
author Mirza, Yasir Azim
Altamura, Davide
Hirbod, Torkan
Verdolini, Roberto
author_facet Mirza, Yasir Azim
Altamura, Davide
Hirbod, Torkan
Verdolini, Roberto
author_sort Mirza, Yasir Azim
collection PubMed
description Classic Kaposi's sarcoma (KS) is a disease with low mortality but high morbidity. The optimum treatment of KS depends upon several factors, including location of lesions, disease progression, severity of symptoms and patient preference. We report the long-term response to the use of intralesional doxorubicin to successfully treat a large cutaneous lesion of KS on a patient refractory to traditional treatments.
format Online
Article
Text
id pubmed-4357673
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-43576732015-04-06 Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report Mirza, Yasir Azim Altamura, Davide Hirbod, Torkan Verdolini, Roberto Case Rep Dermatol Published online: February, 2015 Classic Kaposi's sarcoma (KS) is a disease with low mortality but high morbidity. The optimum treatment of KS depends upon several factors, including location of lesions, disease progression, severity of symptoms and patient preference. We report the long-term response to the use of intralesional doxorubicin to successfully treat a large cutaneous lesion of KS on a patient refractory to traditional treatments. S. Karger AG 2015-02-04 /pmc/articles/PMC4357673/ /pubmed/25848347 http://dx.doi.org/10.1159/000369490 Text en Copyright © 2015 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: February, 2015
Mirza, Yasir Azim
Altamura, Davide
Hirbod, Torkan
Verdolini, Roberto
Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report
title Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report
title_full Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report
title_fullStr Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report
title_full_unstemmed Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report
title_short Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report
title_sort long-term response of classic kaposi's sarcoma to intralesional doxorubicin: a case report
topic Published online: February, 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357673/
https://www.ncbi.nlm.nih.gov/pubmed/25848347
http://dx.doi.org/10.1159/000369490
work_keys_str_mv AT mirzayasirazim longtermresponseofclassickaposissarcomatointralesionaldoxorubicinacasereport
AT altamuradavide longtermresponseofclassickaposissarcomatointralesionaldoxorubicinacasereport
AT hirbodtorkan longtermresponseofclassickaposissarcomatointralesionaldoxorubicinacasereport
AT verdoliniroberto longtermresponseofclassickaposissarcomatointralesionaldoxorubicinacasereport

Ejemplares similares